-

10:03:26 AM

TNXP Stock News

TNXP - Tonix Pharmaceuticals Holding Corp

08/09/22 7:00 AM

Nasdaq : TNXP

conferenceslow float

Tonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor Summit

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Virtual Q3 Investor Summit on Tuesday,

RHEA-AI

neutral

08/02/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication

There is No FDA-Approved Product for Cocaine Intoxication TNX-1300 Has Been Granted Breakthrough Therapy Designation by the FDA Phase 2 Single-Blind, Placebo-Controlled, Potential Pivotal Study Expected to Start in Fourth Quarter 2022, Pending FDA Agreement CHATHAM, N.J., Aug. 02, 2022 (GLOBE

RHEA-AI

positive

08/01/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the

RHEA-AI

neutral

07/28/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a

RHEA-AI

neutral

07/25/22 7:00 AM

Nasdaq : TNXP

managementlow float

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and

RHEA-AI

neutral

07/11/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder

Naloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence Once-Daily Tablet Formulation of Tianeptine is Bioequivalent to the Three Times a Day Antidepressant Marketed in Europe for Over 30

RHEA-AI

negative

07/06/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 at the Hynes Center in

RHEA-AI

neutral

06/27/22 7:00 AM

Nasdaq : TNXP

clinical triallow float

Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication

New Trial Design is Single-Blind, Placebo-Controlled, Potential Pivotal Study, Pending FDA Agreement Expected to Include Women Based on Reproductive Toxicology Studies, Pending FDA Agreement Planning to Include Patients Who Have Received Naloxone to Increase Enrollment CHATHAM, N.J., June 27, 2022

RHEA-AI

neutral

06/22/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500,000 shares of Series A

RHEA-AI

neutral

06/21/22 7:00 AM

Nasdaq : TNXP

low float

Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia

Intranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal Model Enhanced Effect of Mg 2+ is the Core Patented Technology of TNX-1900 for Migraine TNX-2900 Orphan Drug Designated Product for Prader-Willi Syndrome Also Contains Mg 2+ Issued Patents Expected to

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next

TNXP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.tonixpharma.com
CeoSeth Lederman
Security nameTonix Pharmaceuticals Holding Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees26
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address26 Main Street, Suite 101
StateNew Jersey
CityChatham
Zip07928
CountryUnited States
Phone12129809155

About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.